XML 26 R12.htm IDEA: XBRL DOCUMENT
v3.21.2

Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders | 9 Months Ended
--- | ---
Sep. 30, 2021
Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders |
Income (Loss) per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders | Note 5. Income per Share Attributable to Amphastar Pharmaceuticals, Inc. Stockholders ​ Basic net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders is calculated based upon the weighted-average number of shares outstanding during the period. Diluted net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders gives effect to all potential dilutive shares outstanding during the period, such as stock options, non-vested restricted stock units and shares issuable under the Company’s Employee Stock Purchase Plan, or ESPP. ​ For the three and nine months ended September 30, 2021, options to purchase 1,885,093 and 2,045,878 shares of stock, respectively, with a weighted-average exercise price of $20.86 per share and $20.74 per share, respectively, were excluded from the computation of diluted net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders because the effect would be anti-dilutive. ​ For the three and nine months ended September 30, 2020, options to purchase 1,271,347 and 1,928,629 shares of stock, respectively, with a weighted-average exercise price of $21.35 per share and $20.84 per share, respectively, and the reallocation of net income attributable to non-controlling interests were excluded in the computation of diluted net income per common share attributable to Amphastar Pharmaceuticals, Inc. stockholders because the effect would be anti-dilutive. ​ The following table provides the calculation of basic and diluted net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders for each of the periods presented: ​
​ ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Nine Months Ended | ​
​ | ​ | September 30, | ​ | September 30, | ​
​ | ​ | 2021 | ​ | 2020 | ​ | 2021 | ​ | 2020 | ​
​ | ​ | (in thousands, except per share data) | ​
Basic and dilutive numerator: |  | ​ |  |  | ​ |  |  | ​ |  |  | ​ |  |
Net income attributable to Amphastar Pharmaceuticals, Inc. | ​ | $ | 29,548 | ​ | $ | 3,919 | ​ | $ | 42,356 | ​ | $ | 7,676 | ​
Denominator: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Weighted-average shares outstanding — basic | ​ |  | 48,022 | ​ |  | 47,496 | ​ |  | 47,758 | ​ |  | 46,886 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net effect of dilutive securities: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Incremental shares from equity awards | ​ |  | 1,987 | ​ |  | 2,352 | ​ |  | 1,935 | ​ |  | 2,036 | ​
Weighted-average shares outstanding — diluted | ​ |  | 50,009 | ​ |  | 49,848 | ​ |  | 49,693 | ​ |  | 48,922 | ​
Net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders — basic | ​ | $ | 0.62 | ​ | $ | 0.08 | ​ | $ | 0.89 | ​ | $ | 0.16 | ​
Net income per share attributable to Amphastar Pharmaceuticals, Inc. stockholders — diluted | ​ | $ | 0.59 | ​ | $ | 0.08 | ​ | $ | 0.85 | ​ | $ | 0.16 | ​
​

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI http://asc.fasb.org/topic&trid=2144383 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration